Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and Opportunities
Portfolio Pulse from Vandana Singh
Goldman Sachs discussed with Merck's President of Human Health International, Joe Romanelli, about Gardasil's performance and future outlook in China. Despite challenges in the Chinese vaccine market and operational issues with partner Zhifei, Merck remains confident in achieving over $11 billion in Gardasil sales by 2030. Goldman Sachs reiterates a Buy rating on Merck.
August 05, 2024 | 6:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs discussed Gardasil's performance and future outlook in China with Merck's President of Human Health International. Despite challenges in the Chinese vaccine market and operational issues with partner Zhifei, Merck remains confident in achieving over $11 billion in Gardasil sales by 2030. Goldman Sachs reiterates a Buy rating on Merck.
Goldman Sachs' discussion with Merck's President highlights both challenges and opportunities for Gardasil in China. Despite operational issues and a cautious growth outlook, Merck's confidence in achieving significant sales by 2030 and the reiteration of a Buy rating by Goldman Sachs are positive indicators for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100